<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35746614</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1142</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v14061142</ELocationID><Abstract><AbstractText>Enterovirus infections can cause hand, foot, and mouth disease (HFDM), aseptic meningitis, encephalitis, myocarditis, and acute flaccid myelitis, leading to death of infants and young children. However, no specific antiviral drug is currently available for the treatment of this type of infection. The Unites States and United Kingdom health authorities recently approved a new antiviral drug, molnupiravir, for the treatment of COVID-19. In this study, we reported that molnupiravir (EIDD-2801) and its active form, EIDD-1931, have broad-spectrum anti-enterovirus potential. Our data showed that EIDD-1931 could significantly reduce the production of EV-A71 progeny virus and the expression of EV-A71 viral protein at non-cytotoxic concentrations. The results of the time-of-addition assay suggest that EIDD-1931 acts at the post-entry step, which is in accordance with its antiviral mechanism. The intraperitoneal administration of EIDD-1931 and EIDD-2801 protected 1-day-old ICR suckling mice from lethal EV-A71 challenge by reducing the viral load in various tissues of the infected mice. The pharmacokinetics analysis indicated that the plasma drug concentration overwhelmed the EC<sub>50</sub> for enteroviruses, suggesting the clinical potential of molnupiravir against enteroviruses. Thus, molnupiravir along with its active form, EIDD-1931, may be a promising drug candidate against enterovirus infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuexiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Miaomiao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Yunzheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhuang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Qingsong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaotong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xiaojia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xingjuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Ruiyuan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Wu</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-0536-620X</Identifier><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>5CSZ8459RP</RegistryNumber><NameOfSubstance UI="D003562">Cytidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>C3D11PV2O4</RegistryNumber><NameOfSubstance UI="C010737">N(4)-hydroxycytidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>YA84KI1VEW</RegistryNumber><NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006898" MajorTopicYN="N">Hydroxylamines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EIDD-1931</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">molnupiravir</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>1</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35746614</ArticleId><ArticleId IdType="pmc">PMC9227765</ArticleId><ArticleId IdType="doi">10.3390/v14061142</ArticleId><ArticleId IdType="pii">v14061142</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Khetsuriani N., Lamonte A., Oberste M.S., Pallansch M. Neonatal enterovirus infections reported to the national enterovirus surveillance system in the United States, 1983&#x2013;2003. Pediatric Infect. Dis. J. 2006;25:889&#x2013;893. doi: 10.1097/01.inf.0000237798.07462.32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000237798.07462.32</ArticleId><ArticleId IdType="pubmed">17006282</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W., Liao Q., Viboud C., Zhang J., Sun J., Wu J.T., Chang Z., Liu F., Fang V.J., Zheng Y., et al. Hand, foot, and mouth disease in China, 2008&#x2013;2012: An epidemiological study. Lancet Infect. Dis. 2014;14:308&#x2013;318. doi: 10.1016/S1473-3099(13)70342-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichol S.T., Beaty B.J., Elliott R.M., Goldbach R., Plyusnin A., Schmaljohn C.S., Tesh R.B. Virus Taxonomy: Classification and Nomenclature of Viruses: 8th Report of the International Committee on Taxonomy of Viruses. Academic Press; Oxford, UK: 2005.</Citation></Reference><Reference><Citation>WPRO . A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease (HFMD) WHO Western Pacific Region; Manila, PA, USA: 2011.</Citation></Reference><Reference><Citation>Broccolo F., Drago F., Ciccarese G., Genoni A., Puggioni A., Rosa G.M., Parodi A., Manukyan H., Laassri M., Chumakov K., et al. Severe atypical hand-foot-and-mouth disease in adults due to coxsackievirus A6: Clinical presentation and phylogenesis of CV-A6 strains. J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol. 2019;110:1&#x2013;6. doi: 10.1016/j.jcv.2018.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2018.11.003</ArticleId><ArticleId IdType="pubmed">30472520</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Musharrafieh R., Zheng M., Wang J. Enterovirus D68 Antivirals: Past, Present, and Future. ACS Infect. Dis. 2020;6:1572&#x2013;1586. doi: 10.1021/acsinfecdis.0c00120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00120</ArticleId><ArticleId IdType="pmc">PMC8055446</ArticleId><ArticleId IdType="pubmed">32352280</ArticleId></ArticleIdList></Reference><Reference><Citation>Martino T.A., Liu P., Sole M.J. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ. Res. 1994;74:182&#x2013;188. doi: 10.1161/01.RES.74.2.182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.74.2.182</ArticleId><ArticleId IdType="pubmed">8293557</ArticleId></ArticleIdList></Reference><Reference><Citation>Howlett S.E. Coxsackievirus B3-Induced Myocarditis: New Insights Into a Female Advantage. Can. J. Cardiol. 2018;34:354&#x2013;355. doi: 10.1016/j.cjca.2018.01.086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2018.01.086</ArticleId><ArticleId IdType="pubmed">29455949</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairweather D., Stafford K.A., Sung Y.K. Update on coxsackievirus B3 myocarditis. Curr. Opin. Rheumatol. 2012;24:401&#x2013;407. doi: 10.1097/BOR.0b013e328353372d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0b013e328353372d</ArticleId><ArticleId IdType="pmc">PMC4536812</ArticleId><ArticleId IdType="pubmed">22488075</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Liao Q., Ooi M.H., Cowling B.J., Chang Z., Wu P., Liu F., Li Y., Luo L., Yu S., et al. Epidemiology of Recurrent Hand, Foot and Mouth Disease, China, 2008&#x2013;2015. Emerg. Infect. Dis. 2018;24:432&#x2013;442. doi: 10.3201/eid2403.171303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2403.171303</ArticleId><ArticleId IdType="pmc">PMC5823341</ArticleId><ArticleId IdType="pubmed">29460747</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J., Kong F., Xin X., Liang J., Xin H., Dong L., Jiang F. Epidemiological Characteristics of Hand, Foot, and Mouth Disease Outbreaks in Qingdao, 2009&#x2013;2018. Iran. J. Public Health. 2021;50:999&#x2013;1008. doi: 10.18502/ijph.v50i5.6117.</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/ijph.v50i5.6117</ArticleId><ArticleId IdType="pmc">PMC8223573</ArticleId><ArticleId IdType="pubmed">34183958</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.Y., Lee Y.J., Kim T.H., Cheon D.S., Nam S.O. Clinico-radiological spectrum in enterovirus 71 infection involving the central nervous system in children. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 2014;21:416&#x2013;420. doi: 10.1016/j.jocn.2013.04.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2013.04.032</ArticleId><ArticleId IdType="pubmed">24169271</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Z., Zhang Y., Huang K., Wang J., Tian H., Song Y., Yang Q., Yan D., Zhu S., Yao M., et al. Two Coxsackievirus B3 outbreaks associated with hand, foot, and mouth disease in China and the evolutionary history worldwide. BMC Infect. Dis. 2019;19:466. doi: 10.1186/s12879-019-4107-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-019-4107-z</ArticleId><ArticleId IdType="pmc">PMC6534883</ArticleId><ArticleId IdType="pubmed">31126252</ArticleId></ArticleIdList></Reference><Reference><Citation>De Sousa I.P., Jr., Giamberardino H.I., Raboni S.M., Debur M.C., de Lourdes Aguiar Oliveira M., Burlandy F.M., da Silva E.E. Simultaneous enterovirus EV-D68 and CVA6 infections causing acute respiratory distress syndrome and hand, foot and mouth disease. Virol. J. 2021;18:88. doi: 10.1186/s12985-021-01560-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-021-01560-w</ArticleId><ArticleId IdType="pmc">PMC8085469</ArticleId><ArticleId IdType="pubmed">33931064</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H., Zhang Z., Rao Q., Wang X., Wang M., Du T., Tang J., Long S., Zhang J., Luo J., et al. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China. Emerg. Microbes Infect. 2021;10:619&#x2013;628. doi: 10.1080/22221751.2021.1899772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1899772</ArticleId><ArticleId IdType="pmc">PMC8018479</ArticleId><ArticleId IdType="pubmed">33682641</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., Tan X., Wang L., Mao Q., Wu J., et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N. Engl. J. Med. 2014;370:818&#x2013;828. doi: 10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., Zhang Y., Li Y., Mao Q., Wang J., et al. An inactivated enterovirus 71 vaccine in healthy children. N. Engl. J. Med. 2014;370:829&#x2013;837. doi: 10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., Zhang Y.T., Yao X., Chu K., Chen Q.H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024&#x2013;2032. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynard O., Nguyen X.N., Alazard-Dany N., Barateau V., Cimarelli A., Volchkov V.E. Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication. Viruses. 2015;7:6233&#x2013;6240. doi: 10.3390/v7122934.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7122934</ArticleId><ArticleId IdType="pmc">PMC4690858</ArticleId><ArticleId IdType="pubmed">26633464</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon J.J., Toots M., Lee S., Lee M.E., Ludeke B., Luczo J.M., Ganti K., Cox R.M., Sticher Z.M., Edpuganti V., et al. Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses. Antimicrob. Agents Chemother. 2018;62:e00766. doi: 10.1128/AAC.00766-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00766-18</ArticleId><ArticleId IdType="pmc">PMC6105843</ArticleId><ArticleId IdType="pubmed">29891600</ArticleId></ArticleIdList></Reference><Reference><Citation>Painter G.R., Natchus M.G., Cohen O., Holman W., Painter W.P. Developing a direct acting, orally available antiviral agent in a pandemic: The evolution of molnupiravir as a potential treatment for COVID-19. Curr. Opin. Virol. 2021;50:17&#x2013;22. doi: 10.1016/j.coviro.2021.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2021.06.003</ArticleId><ArticleId IdType="pmc">PMC8277160</ArticleId><ArticleId IdType="pubmed">34271264</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuyver L.J., Whitaker T., McBrayer T.R., Hernandez-Santiago B.I., Lostia S., Tharnish P.M., Ramesh M., Chu C.K., Jordan R., Shi J., et al. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob. Agents Chemother. 2003;47:244&#x2013;254. doi: 10.1128/AAC.47.1.244-254.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.47.1.244-254.2003</ArticleId><ArticleId IdType="pmc">PMC149013</ArticleId><ArticleId IdType="pubmed">12499198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Li P., Solanki K., Li Y., Ma Z., Peppelenbosch M.P., Baig M.S., Pan Q. Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses. Virology. 2021;564:33&#x2013;38. doi: 10.1016/j.virol.2021.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2021.09.009</ArticleId><ArticleId IdType="pmc">PMC8486977</ArticleId><ArticleId IdType="pubmed">34619630</ArticleId></ArticleIdList></Reference><Reference><Citation>Toots M., Yoon J.J., Cox R.M., Hart M., Sticher Z.M., Makhsous N., Plesker R., Barrena A.H., Reddy P.G., Mitchell D.G., et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 2019;11:eaax5866. doi: 10.1126/scitranslmed.aax5866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aax5866</ArticleId><ArticleId IdType="pmc">PMC6848974</ArticleId><ArticleId IdType="pubmed">31645453</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J.F., Cao R.Y., Tian X., Yu M., Qin E.D., Qin C.F. Producing infectious enterovirus type 71 in a rapid strategy. Virol. J. 2010;7:116. doi: 10.1186/1743-422X-7-116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-116</ArticleId><ArticleId IdType="pmc">PMC2892457</ArticleId><ArticleId IdType="pubmed">20525351</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Zheng Q., Li S., He M., Wu Y., Li Y., Zhu R., Yu H., Hong Q., Jiang J., et al. Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody. Nat. Commun. 2017;8:505. doi: 10.1038/s41467-017-00477-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00477-9</ArticleId><ArticleId IdType="pmc">PMC5593947</ArticleId><ArticleId IdType="pubmed">28894095</ArticleId></ArticleIdList></Reference><Reference><Citation>Du R., Mao Q., Hu Y., Lang S., Sun S., Li K., Gao F., Bian L., Yang C., Cui B., et al. A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge. Hum. Vaccines Immunother. 2019;15:2343&#x2013;2350. doi: 10.1080/21645515.2019.1565266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1565266</ArticleId><ArticleId IdType="pmc">PMC6816366</ArticleId><ArticleId IdType="pubmed">30735461</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Q., Zhu R., Xu L., He M., Yan X., Liu D., Yin Z., Wu Y., Li Y., Yang L., et al. Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization. Nat. Microbiol. 2019;4:124&#x2013;133. doi: 10.1038/s41564-018-0275-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0275-7</ArticleId><ArticleId IdType="pmc">PMC6727974</ArticleId><ArticleId IdType="pubmed">30397341</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J.N., Wang W., Duo J.Y., Hao Y., Ma C.M., Li W.B., Lin S.Z., Gao X.Z., Liu X.L., Xu Y.F., et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine. 2010;28:7444&#x2013;7451. doi: 10.1016/j.vaccine.2010.08.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.080</ArticleId><ArticleId IdType="pubmed">20831911</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Xu L., He D., Yang L., Liu C., Chen Y., Shih J.W., Zhang J., Zhao Q., Cheng T., et al. In vivo time-related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model. PloS ONE. 2014;9:e109391. doi: 10.1371/journal.pone.0109391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0109391</ArticleId><ArticleId IdType="pmc">PMC4184856</ArticleId><ArticleId IdType="pubmed">25279734</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao T., Li Y., Fan S., Li W., Wang S., Li S., Cao R., Zhong W. Design, synthesis and pharmacological evaluation of a novel mTOR-targeted anti-EV71 agent. Eur. J. Med. Chem. 2019;175:172&#x2013;186. doi: 10.1016/j.ejmech.2019.04.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.04.048</ArticleId><ArticleId IdType="pubmed">31082764</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguwa S., Maringer K., Li X., Bernal-Rubio D., Rauch J.N., Gestwicki J.E., Andino R., Fernandez-Sesma A., Frydman J. Defining Hsp70 Subnetworks in Dengue Virus Replication Reveals Key Vulnerability in Flavivirus Infection. Cell. 2015;163:1108&#x2013;1123. doi: 10.1016/j.cell.2015.10.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.10.046</ArticleId><ArticleId IdType="pmc">PMC4869517</ArticleId><ArticleId IdType="pubmed">26582131</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll S.S., Tomassini J.E., Bosserman M., Getty K., Stahlhut M.W., Eldrup A.B., Bhat B., Hall D., Simcoe A.L., LaFemina R., et al. Inhibition of hepatitis C virus RNA replication by 2&#x2019;-modified nucleoside analogs. J. Biol. Chem. 2003;278:11979&#x2013;11984. doi: 10.1074/jbc.M210914200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M210914200</ArticleId><ArticleId IdType="pubmed">12554735</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C.L., Yeo H., Ye H.Q., Liu S.Q., Shang B.D., Gong P., Alonso S., Shi P.Y., Zhang B. Inhibition of enterovirus 71 by adenosine analog NITD008. J. Virol. 2014;88:11915&#x2013;11923. doi: 10.1128/JVI.01207-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01207-14</ArticleId><ArticleId IdType="pmc">PMC4178731</ArticleId><ArticleId IdType="pubmed">25100827</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L., Wang Y., Qing J., Shu B., Cao L., Lou Z., Gong P., Sun Y., Yin Z. An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation. Antivir. Res. 2014;112:47&#x2013;58. doi: 10.1016/j.antiviral.2014.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.10.009</ArticleId><ArticleId IdType="pubmed">25446894</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.C., Wu C.N., Shih S.R., Ho M.S. Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine. 2002;20:2485&#x2013;2493. doi: 10.1016/S0264-410X(02)00182-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(02)00182-2</ArticleId><ArticleId IdType="pubmed">12057603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.C., Hsieh C.C., Ko W.C. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent. Antibiotics. 2021;10:1294. doi: 10.3390/antibiotics10111294.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics10111294</ArticleId><ArticleId IdType="pmc">PMC8614993</ArticleId><ArticleId IdType="pubmed">34827232</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>